These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31948295)

  • 1. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
    Ritchie M; Hanouneh IA; Noureddin M; Rolph T; Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):197-204. PubMed ID: 31948295
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
    Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
    Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
    [No Abstract]   [Full Text] [Related]  

  • 3. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
    Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.
    Gallego-Escuredo JM; Gómez-Ambrosi J; Catalan V; Domingo P; Giralt M; Frühbeck G; Villarroya F
    Int J Obes (Lond); 2015 Jan; 39(1):121-9. PubMed ID: 24813368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.
    Tian H; Zhang S; Liu Y; Wu Y; Zhang D
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.
    Lee S; Choi J; Mohanty J; Sousa LP; Tome F; Pardon E; Steyaert J; Lemmon MA; Lax I; Schlessinger J
    Nature; 2018 Jan; 553(7689):501-505. PubMed ID: 29342135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease.
    Chrysavgis L; Giannakodimos I; Chatzigeorgiou A; Tziomalos K; Papatheodoridis G; Cholongitas E
    Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):835-849. PubMed ID: 36124827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.
    Aaldijk AS; Verzijl CRC; Jonker JW; Struik D
    Front Endocrinol (Lausanne); 2023; 14():1150222. PubMed ID: 37260446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
    Liu WY; Xie DM; Zhu GQ; Huang GQ; Lin YQ; Wang LR; Shi KQ; Hu B; Braddock M; Chen YP; Zheng MH
    Expert Opin Ther Targets; 2015 May; 19(5):675-85. PubMed ID: 25547779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions.
    Min X; Weiszmann J; Johnstone S; Wang W; Yu X; Romanow W; Thibault S; Li Y; Wang Z
    J Biol Chem; 2018 Sep; 293(38):14678-14688. PubMed ID: 30068552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
    Henriksson E; Andersen B
    Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways.
    Lee KJ; Jang YO; Cha SK; Kim MY; Park KS; Eom YW; Baik SK
    Gut Liver; 2018 Jul; 12(4):449-456. PubMed ID: 29699061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Saga of Endocrine FGFs.
    Phan P; Saikia BB; Sonnaila S; Agrawal S; Alraawi Z; Kumar TKS; Iyer S
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD.
    Wang Z; Sun T; Yu J; Li S; Gong L; Zhang Y
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):351. PubMed ID: 38179757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
    Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
    Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.